Skip to content
Search

Latest Stories

NHS unveils new policy to combat sexual misconduct in the workplace

NHS unveils new policy to combat sexual misconduct in the workplace

An anonymous reporting option allows NHS staff to report incidents of sexual misconduct without disclosing their identity  

As part of major plans to improve staff safety, the National Health Service (NHS) has unveiled a new policy aimed at tackling sexual misconduct within the health service.

The policy, which is now available for immediate adoption by local hospitals, outlines how those working in the health service should recognise, report and act on sexual misconduct in the workplace.


A key component of the support package is the introduction of an anonymous reporting option, allowing employees to report sexual abuse without having to disclose their names or personal details.

The framework also provides guidance for conducting investigations, which includes forming a specialist review group with access to subject matter experts and independent investigators.

NHS chief executive Amanda Pritchard emphasised the importance of creating a supportive environment for staff, stating, “For anyone who has experienced sexual abuse or misconduct at work, it is an extremely distressing and isolating experience, and so we must do everything in our power to ensure our staff feel able to speak up, and have absolute confidence that they will be given the support they need when they do.”

Pritchard hopes that the new national policy will help NHS colleagues take the right steps in recognising, reporting and acting on sexual misconduct at work.

“By introducing the option of anonymous reporting, we are making it easier for staff to come forward to report issues – it marks our serious commitment to stamping out this horrendous behaviour,” she added.

She firmly stated that “there is absolutely no place for sexual misconduct or abuse of any kind within the NHS.”

“We know that women are more likely to be affected – this is unacceptable, and we must not tolerate it.”

However, Pritchard acknowledged that this is just one of the first steps to ending harmful sexual behaviour in the NHS, and that more action is needed.

Pritchard encourages leaders across the health service to adopt these measures to ensure that staff feel safe and supported.

The NHS noted that the policy has been developed in partnership with staff who have lived experience, trade unions, colleagues in the voluntary, community and social enterprise sector, academics experts, and system leaders.

It covers various forms of sexual misconduct connected to work or the workplace such as:

  • sexual comments or jokes
  • unwanted touching or kissing
  • showing sexual pictures
  • staring at someone in a sexual way
  • asking personal questions about someone’s sex life
  • sexual assault or rape

According to the 2023/24 NHS staff survey for England, one in eight workers—approximately 58,000—reported experiencing unwanted sexual behaviour in the past year, while one in 26 reported facing similar harassment from a colleague.

More For You

RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less
Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less